Joseph LaRosa - Regeneron Pharmaceuticals Senior Vice President General Counsel, Secretary

REGN -- USA Stock  

USD 295.87  9.72  3.40%

Mr. Joseph J. LaRosa is an Senior Vice President, General Counsel, Secretary of the Company. Mr. LaRosa was Senior Vice President, General Counsel, and Secretary at Nycomed US Inc. Mr. LaRosas prior experience includes working in a number of senior legal positions at ScheringPlough Corporationrationration from 1993 to 2009, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team
Age: 59  President Since 2019      
LaRosa received his J.D. from New York University School of Law.

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Samiran DasDr Reddys Laboratories Ltd
Amit SachdevVertex Pharmaceuticals Incorpor
Scott JamisonPerrigo Company plc
Umang VohraDr Reddys Laboratories Ltd
Sripada ChandrasekharDr Reddys Laboratories Ltd
Michael PariniVertex Pharmaceuticals Incorpor
John HendricksonPerrigo Company plc
James MichaudPerrigo Company plc
James DillardPerrigo Company plc
Charles WagnerVertex Pharmaceuticals Incorpor
John WesolowskiPerrigo Company plc
Alok SonigDr Reddys Laboratories Ltd
Thomas FarringtonPerrigo Company plc
Cartikeya ReddyDr Reddys Laboratories Ltd
Kimberly WhiteVertex Pharmaceuticals Incorpor
Jeffrey NeedhamPerrigo Company plc
Heidi ChenZoetis
Glenn DavidZoetis
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Marc CouckePerrigo Company plc
Michael StewartPerrigo Company plc

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased one share of
few hours ago
Traded for 1221.15
Purchased over 100 shares of
few hours ago
Traded for 19.55
Purchased over 40 shares of
few hours ago
Traded for 43.23
Purchased over 60 shares of
few hours ago
Traded for 30.83
Purchased few shares of
few hours ago
Traded for 111.18
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.